-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140

Benzinga·11/05/2026 21:23:07
Listen to the news
Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $154 to $140.